Give the working title of the review, for example the one used for obtaining funding. Ideally the title should state succinctly the interventions or exposures being reviewed and the associated health or social problems.
* Conflicts of interest.
List any conditions that could lead to actual or perceived undue influence on judgements concerning the main topic investigated in the review. None 14. Collaborators.
Give the name and affiliation of any individuals or organisations who are working on the review but who are not listed as review team members.
* Review question.
State the question(s) to be addressed by the review, clearly and precisely. Review questions may be specific or broad. It may be appropriate to break very broad questions down into a series of related more specific questions. Questions may be framed or refined using PI(E)COS where relevant. What is the diagnostic accuracy of the commercially available NDO-LID antigen based ELISA assay compared to ELISA based on the PGL-1 reference antigen for the detection of antibodies against M. leprae in patients with leprosy? 215 words remaining 16 . * Searches.
Give details of the sources to be searched, search dates (from and to), and any restrictions (e.g. language or publication period). The full search strategy is not required, but may be supplied as a link or attachment. Three-step search strategy will be utilized in this review. An initial limited search of MEDLINE will be performed searching the MeSH index terms and related keywords. A second search using all identified keywords and index terms will be made across all included databases. Thirdly, we will perform a search to find grey literature. 247 words remaining 17. URL to search strategy.
Give a link to the search strategy or an example of a search strategy for a specific database if available (including the keywords that will be used in the search strategies).
Alternatively, upload your search strategy to CRD in pdf format. Please note that by doing so you are consenting to the file being made publicly accessible.
Yes I give permission for this file to be made publicly available 18 . * Condition or domain being studied.
Give a short description of the disease, condition or healthcare domain being studied. This could include health and wellbeing outcomes. In this project we intend to conduct a systematic review and meta-analysis of the serological anti PGL-1 and NDO-LID-1 antigen based ELISA assay. No meta-analysis studies have been performed to evaluate the diagnostic accuracy of serological ELISA assay based on the detection of PGL-I and NDO-LID antibodies. These tests are used as diagnosis tools, classification of patients, treatment evolution, risk of recurrence and in the selection of contacts with higher risk to develop the disease 125 words remaining Where relevant, give details of the alternatives against which the main subject/topic of the review will be compared (e.g. another intervention or a non-exposed control group). The preferred format includes details of both inclusion and exclusion criteria. Reference test This review will consider studies that include the diagnostic accuracy of ELISA assays using PGL-1 antigens. 183 words remaining 22 . * Types of study to be included.
Give details of the types of study (study designs) eligible for inclusion in the review. If there are no restrictions on the types of study design eligible for inclusion, or certain study types are excluded, this should be stated. The preferred format includes details of both inclusion and exclusion criteria. Cross-sectional and longitudinal analytical studies will be included 142 words remaining 23. Context.
Give summary details of the setting and other relevant characteristics which help define the inclusion or exclusion criteria. Exclusion Criteria. Studies without Cutoff Value. 244 words remaining
* Main outcome(s).
Give the pre-specified main (most important) outcomes of the review, including details of how the outcome is defined and measured and when these measurement are made, if these are part of the review inclusion criteria. Diagnosis of interest This review will consider studies that include measure of titters of antibodies against M. leprae. 
PROSPERO International prospective register of systematic reviews
Give the procedure for selecting studies for the review and extracting data, including the number of researchers involved and how discrepancies will be resolved. List the data to be extracted. Quantitative data will be extracted from papers included in the review using The STARD (Standards for Reporting of Diagnostic Accuracy). Any disagreements that arise between the reviewers will be resolved through discussion, or with a third reviewer. 263 words remaining 27. * Risk of bias (quality) assessment.
State whether and how risk of bias will be assessed (including the number of researchers involved and how discrepancies will be resolved), how the quality of individual studies will be assessed, and whether and how this will influence the planned synthesis. Papers selected for retrieval will be assessed by two independent reviewers for methodological validity prior to inclusion in the review using standardized critical appraisal instruments from the QUADAS 2. 171 words remaining 28. * Strategy for data synthesis.
Give the planned general approach to synthesis, e.g. whether aggregate or individual participant data will be used and whether a quantitative or narrative (descriptive) synthesis is planned. It is acceptable to state that a quantitative synthesis will be used if the included studies are sufficiently homogenous. Two forest plots are presented side by side: one for sensitivity and the other for specificity. Moreover, the number of true positives, false positives, true negatives and false negatives are also reported, as well as, where appropriate, any covariates (for instance the type of diagnostic test used). Summary ROC (SROC) curves will also be presented. Through the graphs of paired forests or the SROC curve the presence or absence of heterogeneity will be identified. If there are differences in the diagnostic threshold between the studies, the forest charts will not be used to analyze the heterogeneity, in which case it will be estimated through the SROC curve. For more objective assessments of heterogeneity will be performed statistical tests of chi-square (Cochrane Q) and Isquared. The meta-analysis will be performed based on the Bivariate method to estimate a summary of the parameters of the primary studies: sensitivity and specificity (Reitsma et al., 2009). To treat the variability in cutoff values, a Hierarchal Sumary Receiver Operating Characteristic (HSROC). 134 words remaining 29. * Analysis of subgroups or subsets.
Give details of any plans for the separate presentation, exploration or analysis of different types of participants (e.g. by age, disease status, ethnicity, socioeconomic status, presence or absence or comorbidities); different types of intervention (e.g. drug dose, presence or absence of particular components of intervention); different settings (e.g. country, acute or primary care sector, professional or family care); or different types of study (e.g. randomised or non-randomised). This will be determined by the homogenety/heterogenity of data. 241 words remaining 30. * Type and method of review. Alternatively, upload your published protocol to CRD in pdf format. Please note that by doing so you are consenting to the file being made publicly accessible.
Yes I give permission for this file to be made publicly available Please note that the information required in the PROSPERO registration form must be completed in full even if access to a protocol is given.
35. Dissemination plans. 
Details of final report/publication(s).
This field should be left empty until details of the completed review are available.
Give the link to the published review.
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